Glioma-specific antigens for immune tumor therapy.
This review describes glioma-specific antigens important in immunotherapy of glioma tumors. The structure and function of these antigens and recent immunotherapy data are summarized. Also, some important aspects of tumor formation are outlined. The roles of neuronal precursor cells and tumor stroma cells are discussed. The stroma cells of the tumor may be of interest as a target for tumor therapy, especially since they are less heterogeneous than the tumor cells. To date, the clinical benefit of immunotherapy has been very limited. Immunotherapy is, however, still an extremely promising approach to tumor therapy and it will most likely be implemented as a future treatment option for many types of tumors. The current shortcomings of immunotherapy will probably diminish as we start to understand and are able to modulate tumor-induced immunosuppression. There is also a need for a continued search for new tumor-specific antigens and to optimize protocols for vaccine administration.
Skog
Johan
J
Umea University, Department of Virology, SE-901 85, Umea, Sweden. johan.skog@climi.umu.se
D000951:Antigens, Neoplasm / Q000276:immunology*; D001932:Brain Neoplasms / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D005910:Glioma / Q000276:immunology* / Q000517:prevention & control; D006801:Humans
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines